Diagnosis of bloodstream infections by mass spectrometry : present and future

Rapid identification and antimicrobial susceptibility testing of the causative agent(s) of bloodstream infections may impact on the clinical outcome of patients, which is directly related to the prompt administration of an effective antimicrobial therapy. Empirical antimicrobial therapy is chosen on the basis of clinical and epidemiological data and it is administered immediately after blood sampling but, in a significant number of cases, it has to be streamlined on the basis of the microbiological report. Rapid identification has a clinically relevant impact on the timely selection of an appropriate antimicrobial therapy, especially in low-prevalence areas for antimicrobial resistance. Recently, the identification process of isolated bacteria has been revolutionized by the introduction of mass spectrometry (MS), particularly MALDI-TOF, in clinical microbiology laboratories. Furthermore, MALDI-TOF is one of the most promising techniques for the identification of bacterial and fungal infectious agents directly from positive blood cultures and a potentially useful tool for the detection of antimicrobial resistance, specifically that conferred by -lactamases. Although blood culture remains, at present, the gold standard to diagnose bloodstream infections, newly developed MALDI-TOF methods are useful adjunctive tests to fasten the diagnostic process and further increase the diagnostic yield.